Tracer library / [90Y]Y-90-DOTATOC/DOTATATE
[90Y]Y-90-DOTATOC/DOTATATE
Also written as Y-90-DOTATOC/DOTATATE
- Radionuclide
- Y-90 t½ 3843.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- Clinical research
- Syntheses indexed
- 1
What it is
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis n/a | — | HPLC | >90% | — | CP04 | 26315862 2015 Nucl Med Rev Cent East Eur Complex formation needed 5 min in microwave oven or 12 min in thermo-block at 95°C. - Yields of CP04 radiolabelling were greater than 90% for all three radionuclides. |
Clinical literature
Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.
- Prognostic Value of 18F-FDG PET/CT in a Large Cohort of Patients with Advanced Metastatic Neuroendocrine Neoplasms Treated with Peptide Receptor Radionuclide Therapy.2020 · J Nucl Med · Retrospective
- Intra-arterial peptide receptor radionuclide therapy (IA-PRRT) in patients with SSTR-expressing neuroendocrine neoplasms: short- and long-term safety and efficacy for up to 13 years.2026 · Theranostics · Clinical study
Need this precursor?We can point you to suppliers for [90Y]Y-90-DOTATOC/DOTATATE, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Stage set/updated at stage 39 from PMID 41356201: '52 patients with SSTR-expressing NENs treated with intra-arterial PRRT with 177Lu- or 90Y-DOTATOC/DOTATATE from February 1999 to January 2019 were reviewed.'.